Moreover, based on the recent data reviewed, the high reactivity of BCG‐derived antigen to its corresponding SARS‐COV‐2 substantially increased type II IFN production and its effect on CD4+ T‐cells and nonspecific immune responses could harness cross‐protection against severe COVID‐19.66 This evidence concerns the gene CD4 and COVID-19.